Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

(Reuters) -The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus ...

The U.S. Food and Drug Administration has approved Moderna’s (NASDAQ:MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...

Cambridge: Moderna, Inc. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...